October 5, 2016 09:21 AM EDT

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

John Carroll

Editor & Founder

Add one more drug to AstraZeneca’s growing pile of pipeline drugs it’s jettisoning. This time, the deal focuses on an early-stage respiratory drug dubbed AZD7986 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

As­traZeneca jet­ti­sons an­oth­er drug, this time grab­bing $30M for out-li­cens­ing deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M